Lurbinectedin

Chemical formula: C₄₁H₄₄N₄O₁₀S  Molecular mass: 784.88 g/mol  PubChem compound: 57327016

Therapeutic indications

Lurbinectedin is indicated for:

Extensive-stage small cell lung cancer (ES-SCLC) - combination treatment

Population group: only adults (18 years old or older)

Lurbinectedin, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Lurbinectedin is contraindicated in the following cases:

Lactation

Lactation

Baseline neutrophil counts of less than 1.5 x 10⁹/L and platelet counts of less than 100 x 10⁹/L

at least one of
Neutropenia
Thrombocytopenic disorder

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2026: ZEPZELCA Powder for concentrate for solution for infusion
Structured Product Labeling (SPL/PLR) 2022: ZEPZELCA Powder for solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈